Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies, for the joint development of an AI-based cancer pathology diagnostic support program.
Through this partnership, the companies aim to implement personalized healthcare solutions in society, specially for patients battling with cancer.
Under this deal, Chugai's scientific knowledge will be integrated with Biomy's platform for tumor microenvironment analysis, aiming to reduce the workload of pathologists and provide optimal treatment and diagnosis for individual patients.
Chugai's stock closed at $27.05, up 0.74 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.